Your browser doesn't support javascript.
loading
Detection of bacterial co-infections and prediction of fatal outcomes in COVID-19 patients presenting to the emergency department using a 29 mRNA host response classifier.
Nikhil Ram-Mohan; Angela J Rogers; Catherine A Blish; Kari C Nadeau; Elizabeth J Zudock; David Kim; James V Quinn; Lixian Sun; Oliver Liesenfeld; - the Stanford COVID-19 Biobank Study Group; Samuel Yang.
Affiliation
  • Nikhil Ram-Mohan; Stanford University School of Medicine
  • Angela J Rogers; Stanford University School of Medicine
  • Catherine A Blish; Stanford University
  • Kari C Nadeau; Stanford University School of Medicine
  • Elizabeth J Zudock; Stanford University School of Medicine
  • David Kim; Stanford University School of Medicine
  • James V Quinn; Stanford University School of Medicine
  • Lixian Sun; Inflammatix Inc.
  • Oliver Liesenfeld; Inflammatix Inc.
  • - the Stanford COVID-19 Biobank Study Group;
  • Samuel Yang; Stanford University
Preprint de En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22272394
ABSTRACT
ObjectiveClinicians in the emergency department (ED) face challenges in concurrently assessing patients with suspected COVID-19 infection, detecting bacterial co-infection, and determining illness severity since current practices require separate workflows. Here we explore the accuracy of the IMX-BVN-3/IMX-SEV-3 29 mRNA host response classifiers in simultaneously detecting SARS-CoV-2 infection, bacterial co-infections, and predicting clinical severity of COVID-19. Methods161 patients with PCR-confirmed COVID-19 (52.2% female, median age 50.0 years, 51% hospitalized, 5.6% deaths) were enrolled at the Stanford Hospital ED. RNA was extracted (2.5 mL whole blood in PAXgene Blood RNA) and 29 host mRNAs in response to the infection were quantified using Nanostring nCounter. ResultsThe IMX-BVN-3 classifier identified SARS-CoV-2 infection in 151 patients with a sensitivity of 93.8%. Six of 10 patients undetected by the classifier had positive COVID tests more than 9 days prior to enrolment and the remaining oscillated between positive and negative results in subsequent tests. The classifier also predicted that 6 (3.7%) patients had a bacterial co-infection. Clinical adjudication confirmed that 5/6 (83.3%) of the patients had bacterial infections, i.e. Clostridioides difficile colitis (n=1), urinary tract infection (n=1), and clinically diagnosed bacterial infections (n=3) for a specificity of 99.4%. 2/101 (2.8%) patients in the IMX-SEV-3 Low and 7/60 (11.7%) in the Moderate severity classifications died within thirty days of enrollment. ConclusionsIMX-BVN-3/IMX-SEV-3 classifiers accurately identified patients with COVID-19, bacterial co-infections, and predicted patients risk of death. A point-of-care version of these classifiers, under development, could improve ED patient management including more accurate treatment decisions and optimized resource utilization.
Licence
cc_by_nc_nd
Texte intégral: 1 Collection: 09-preprints Base de données: PREPRINT-MEDRXIV Type d'étude: Diagnostic_studies / Prognostic_studies Langue: En Année: 2022 Type de document: Preprint
Texte intégral: 1 Collection: 09-preprints Base de données: PREPRINT-MEDRXIV Type d'étude: Diagnostic_studies / Prognostic_studies Langue: En Année: 2022 Type de document: Preprint